{"protocolSection":{"identificationModule":{"nctId":"NCT06476119","orgStudyIdInfo":{"id":"M24OTI"},"organization":{"fullName":"The Netherlands Cancer Institute","class":"OTHER"},"briefTitle":"OPTImaL:Optimisation of Treatment for Patients With Low Stage Triple-negative Breast Cancer With High Stromal Tumor-infiltrating Lymphocytes","officialTitle":"OPTImaL:Optimisation of Treatment for Patients With Low Stage Triple-negative Breast Cancer With High Stromal Tumor-infiltrating Lymphocytes","acronym":"OPTImaL"},"statusModule":{"statusVerifiedDate":"2024-06","overallStatus":"NOT_YET_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2024-09-15","type":"ESTIMATED"},"primaryCompletionDateStruct":{"date":"2032-09-15","type":"ESTIMATED"},"completionDateStruct":{"date":"2034-09-15","type":"ESTIMATED"},"studyFirstSubmitDate":"2024-06-07","studyFirstSubmitQcDate":"2024-06-20","studyFirstPostDateStruct":{"date":"2024-06-26","type":"ACTUAL"},"lastUpdateSubmitDate":"2024-06-20","lastUpdatePostDateStruct":{"date":"2024-06-26","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"The Netherlands Cancer Institute","class":"OTHER"},"collaborators":[{"name":"Maarten van de Weijden Foundation","class":"UNKNOWN"},{"name":"AVL Foundation","class":"UNKNOWN"}]},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The aim of this study is to investigate whether subjects with breast cancer that have certain favorable features, after performing the surgery and radiation, the chemotherapy can be safely omitted in the treatment. In addition, the investigation looks at whether the omission of chemotherapy ensures a better quality of life. Participants decide, in consulatiation with their treating physician, whether they choose to be treated with adjuvant chemotherapy or not."},"conditionsModule":{"conditions":["Breast Cancer Stage I","Triple Negative Breast Cancer (TNBC)"],"keywords":["High (stromal Tumor-Infiltrating-Lymphocytes) sTIL score"]},"designModule":{"studyType":"OBSERVATIONAL","patientRegistry":false,"designInfo":{"observationalModel":"COHORT","timePerspective":"PROSPECTIVE"},"bioSpec":{"retention":"SAMPLES_WITH_DNA","description":"ctDNA samples"},"enrollmentInfo":{"count":490,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Optimisation cohort","description":"patients will be treated with surgery and adjuvant radiotherapy following local/national guidelines, while chemotherapy will be omitted","interventionNames":["Other: No adjuvant chemotherapy"]},{"label":"Control cohort","description":"patients will be treated with surgery, adjuvant radiotherapy and adjuvant chemotherapy following local/national guidelines","interventionNames":["Drug: Adjuvant chemotherapy"]}],"interventions":[{"type":"DRUG","name":"Adjuvant chemotherapy","description":"adjuvant chemotherapy according to local/ national guidelines","armGroupLabels":["Control cohort"],"otherNames":["according to local/ national guidelines"]},{"type":"OTHER","name":"No adjuvant chemotherapy","description":"no adjuvant chemotherapy","armGroupLabels":["Optimisation cohort"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Disease recurrence Free Interval (DRFI) - optimalisation cohort","description":"Number of patients with distant recurrence or death in optimisation cohort","timeFrame":"up to 96 months after inclusion of the last patient"}],"secondaryOutcomes":[{"measure":"Invasive disease-free survival (IDFS) - optimalisation cohort","description":"Number of patients with breast tumor recurrence or death in the optimisation cohort","timeFrame":"up to 96 months after inclusion of the last patient"},{"measure":"Invasive disease-free survival (IDFS) - control cohort","description":"Number of patients with breast tumor recurrence or death in the control cohort","timeFrame":"up to 96 months after inclusion of the last patient"},{"measure":"disease recurrence free survival (DRFS) - optimalisation cohort","description":"time between inclusion and first distant recurrence or death from any cause in the optimisation cohort","timeFrame":"up to 96 months after inclusion of the last patient"},{"measure":"disease recurrence free survival (DRFS) - control cohort","description":"time between inclusion and first distant recurrence or death from any cause in the control cohort","timeFrame":"up to 96 months after inclusion of the last patient"},{"measure":"Recurrence-free survival (RFS) - optimalisation cohort","description":"time between inclusion and invasive ipsilateral breast tumor recurrence, local-regional invasive recurrence, distant recurrence or death from any cause in the optimisation cohort;","timeFrame":"up to 96 months after inclusion of the last patient"},{"measure":"Recurrence-free survival (RFS) - control cohort","description":"time between inclusion and invasive ipsilateral breast tumor recurrence, local-regional invasive recurrence, distant recurrence or death from any cause in the control cohort;","timeFrame":"up to 96 months after inclusion of the last patient"},{"measure":"Overal Survival (OS) - optimalisation cohort","description":"time between inclusion and death from any cause in the optimisation cohort;","timeFrame":"up to 96 months after inclusion of the last patient"},{"measure":"Overal Survival (OS) - control cohort","description":"time between inclusion and death from any cause in the control cohort;","timeFrame":"up to 96 months after inclusion of the last patient"},{"measure":"Health related Quality of Life (HRQoL) - EORTC QLQ-C30","description":"Difference in QoL assessed with the EORTC QLQ-C30 questionnaires between the optimisation and the control group","timeFrame":"up to 2 years after inclusion"},{"measure":"Health related Quality of Life (HRQoL) - EORTC QLQ-BR45","description":"Difference in QoL assessed with the EORTC QLQ-BR45 questionnaires between the optimisation and the control group","timeFrame":"up to 2 years after inclusion"},{"measure":"Fear of recurrence","description":"Assessed with questionnaires to determine the difference in optimisation and control group","timeFrame":"up to 2 years after inclusion"},{"measure":"Worries about health","description":"Assessed with questionnaires to determine the difference in optimisation and control group","timeFrame":"up to 2 years after inclusion"},{"measure":"Cost effectiveness measured by quality-adjusted-life years (QALYs)","description":"Measured per Quality-Adjusted Life Years (QALYs)","timeFrame":"up to 2 years after inclusion"},{"measure":"Cost effectiveness measured per incremental cost-effectiveness ratio (ICER)","description":"Measured per incremental cost-effectiveness ratio (ICER)","timeFrame":"up to 2 years after inclusion"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Female or male patients;\n* \\>=18 years;\n* Written informed consent;\n* TNBC (defined as: invasive carcinoma; ER/PR expression 0-9%; Human Epidermal Growth Factor Receptor 2 \\[HER2\\] negative \\[0, 1+ or 2+ on immunohistochemistry, without HER2 amplification on in-situ hybridization\\]) on the diagnostic biopsy and the surgical specimen;\n* Pathological stage I TNBC (according to the TNM staging 8th edition):\n\n  * pT1a/b/c (≤2 cm), confirmed by an invasive component of ≤2 cm on the surgical specimen (microinvasive disease \\[pT1mi, ≤1 mm) is not allowed);\n  * pN0, confirmed by absence of malignant cells in the sentinel lymph node or any other lymph node after surgery (isolated tumor cells \\[N0(i+)\\] are not allowed);\n* No evidence of nodal or distant metastases (cN0M0) on preoperative imaging examinations (performed following local/national guidelines, but must include an 18F-fluorodeoxyglucose positron emission tomography/computed tomography \\[18F-FDG-PET/CT, at least from skull base to upper legs\\] or computed tomography \\[CT\\] of neck/chest/abdomen/pelvis \\[CT only if 18F-FDG-PET/CT would not be available; 18F-FDG-PET/CT mandatory in the Netherlands\\]);\n* sTIL score of ≥50% (≥75% for patients \\<40 years) on an H\\&E FFPE tissue slide on the surgical specimen, according to International Immuno-Oncology Biomarker Working Group on Breast Cancer (formerly International TILs Working Group) guidelines, by local and central review;\n* Curative breast surgery (breast-conserving surgery or mastectomy and surgical axillary staging \\[including at least sentinel lymph node procedure\\]);\n* Absence of recurrence between curative breast surgery and expression of patient preference;\n* Eligible for radiotherapy (if indicated).\n\nExclusion Criteria:\n\n* Prior disease history of breast cancer, or ongoing treatment for breast cancer;\n* Multifocal, multicentric or bilateral breast cancer at the time of screening;\n* Administration of neoadjuvant systemic therapy;\n* Presence of lymphovascular invasion on the diagnostic biopsy and/or the surgical specimen;\n* Other invasive malignancy within 5 years prior to inclusion, with the exception of ade-quately treated non-melanoma skin cancer, localized cervical cancer, localized and Gleason ≤6 prostate cancer;\n* Uncontrolled severe illness or medical condition;\n* Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be assessed and discussed with the patient before the enrolment in the in the trial.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"],"studyPopulation":"patients with pathological stage I TNBC (pT1a/b/cN0) and a high sTIL score (defined as ≥50% for patients ≥40 years; ≥75% for patients \\<40 years)","samplingMethod":"PROBABILITY_SAMPLE"},"contactsLocationsModule":{"centralContacts":[{"name":"Marleen Kok, MD","role":"CONTACT","phone":"+31205129111","email":"m.kok@nki.nl"},{"name":"Rianne Rolfes, MD","role":"CONTACT","phone":"+31205129111","email":"r.rolfes@nki.nl"}],"overallOfficials":[{"name":"Marleen Kok, MD","affiliation":"Antoni van Leeuwenhoek","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Zuyderland Medisch Centrum","city":"Sittard-Geleen","state":"Limburg","zip":"6162 BG","country":"Netherlands","contacts":[{"name":"F van den Berkmortel, MD","role":"CONTACT"},{"name":"F van den Berkmortel, MD","role":"PRINCIPAL_INVESTIGATOR"}]},{"facility":"Medical spectrum Twente","city":"Enschede","state":"Overijssel","zip":"7500 KA","country":"Netherlands","contacts":[{"name":"M Wymenga, MD","role":"CONTACT"},{"name":"M Wymenga, MD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":52.21833,"lon":6.89583}},{"facility":"Noordwest Ziekenhuisgroep","city":"Alkmaar","country":"Netherlands","contacts":[{"name":"S Vrijaldenhoven, MD","role":"CONTACT"},{"name":"S Vrijaldenhoven, MD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":52.63167,"lon":4.74861}},{"facility":"Flevoziekenhuis","city":"Almere","country":"Netherlands","contacts":[{"name":"S A.L Bartels, MD","role":"CONTACT"},{"name":"S A.L. Bartels, MD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":52.37535,"lon":5.25295}},{"facility":"Meander Medisch Centrum","city":"Amersfoort","country":"Netherlands","contacts":[{"name":"J M Baas, MD","role":"CONTACT"},{"name":"J M Baas, MD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":52.155,"lon":5.3875}},{"facility":"Antoni van Leeuwenhoek","city":"Amsterdam","zip":"1066 CX","country":"Netherlands","contacts":[{"name":"Marleen Kok, MD","role":"CONTACT","phone":"+3120512","phoneExt":"9111","email":"m.kok@nki.nl"},{"name":"Ingrid AM Mandjes, MSc","role":"CONTACT","phone":"+3120512","phoneExt":"9111","email":"i.mandjes@nki.nl"},{"name":"Marleen Kok, MD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":52.37403,"lon":4.88969}},{"facility":"Onze Lieve Vrouwe Gasthuis (OLVG)","city":"Amsterdam","country":"Netherlands","contacts":[{"name":"B Flameling, MD","role":"CONTACT"},{"name":"B Flameling, MD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":52.37403,"lon":4.88969}},{"facility":"Rijnstate","city":"Arnhem","country":"Netherlands","contacts":[{"name":"K Beelen, MD","role":"CONTACT"},{"name":"K Beelen, MD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":51.98,"lon":5.91111}},{"facility":"Haaglanden Medisch Centrum","city":"Den Haag","country":"Netherlands","contacts":[{"name":"R. Oosterkamp, MD, PhD","role":"CONTACT"},{"name":"R. Oosterkamp, MD, PhD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":52.07667,"lon":4.29861}},{"facility":"Deventer Ziekenhuis","city":"Deventer","country":"Netherlands","contacts":[{"name":"L. Kessels, MD, PhD","role":"CONTACT"},{"name":"L. Kessels, MD, PhD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":52.255,"lon":6.16389}},{"facility":"Ziekenhuis Gelderse Vallei","city":"Ede","country":"Netherlands","contacts":[{"name":"M Verstappen, MD","role":"CONTACT"},{"name":"M Verstappen, MD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":52.03333,"lon":5.65833}},{"facility":"Catharina Ziekenhuis","city":"Eindhoven","country":"Netherlands","contacts":[{"name":"R-J Schipper, MD","role":"CONTACT"},{"name":"R-J Schipper, MD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":51.44083,"lon":5.47778}},{"facility":"Jeroen Bosch ziekenhuis","city":"Eindhoven","country":"Netherlands","contacts":[{"name":"J Tol, MD","role":"CONTACT"},{"name":"J Tol, MD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":51.44083,"lon":5.47778}},{"facility":"St. Jansdal","city":"Harderwijk","country":"Netherlands","contacts":[{"name":"J A Ropela, MD","role":"CONTACT"},{"name":"J A Ropela, MD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":52.34167,"lon":5.62083}},{"facility":"Ziekenhuisgroep Twente","city":"Hengelo","country":"Netherlands","contacts":[{"name":"E Siemerink, MD","role":"CONTACT"},{"name":"E Siemerink, MD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":52.26583,"lon":6.79306}},{"facility":"Tergooi ziekenhuizen","city":"Hilversum","country":"Netherlands","contacts":[{"name":"A Willemsen, MD","role":"CONTACT"},{"name":"A Willemsen, MD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":52.22333,"lon":5.17639}},{"facility":"Dijklander ziekenhuis","city":"Hoorn","country":"Netherlands","contacts":[{"name":"M M Vleugel, MD","role":"CONTACT"},{"name":"M M Vleugel, MD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":52.6425,"lon":5.05978}},{"facility":"MCL","city":"Leeuwarden","zip":"8934 AD","country":"Netherlands","contacts":[{"name":"L Hamming, MD","role":"CONTACT"},{"name":"L Hamming, MD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":53.20139,"lon":5.80859}},{"facility":"MUMC","city":"Maastricht","country":"Netherlands","contacts":[{"name":"M de Boer, MD","role":"CONTACT"},{"name":"M de Boer, MD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":50.84833,"lon":5.68889}},{"facility":"St. Antonius ziekenhuis","city":"Nieuwegein","country":"Netherlands","contacts":[{"name":"M J Agterof, MD","role":"CONTACT"},{"name":"M J Agterof, MD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":52.02917,"lon":5.08056}},{"facility":"Radboud UMC","city":"NIjmegen","zip":"6225GA","country":"Netherlands","contacts":[{"name":"E Kuip, MD","role":"CONTACT"},{"name":"E Kuip, MD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":51.8425,"lon":5.85278}},{"facility":"Erasmus Medical Center Cancer Institute","city":"Rotterdam","zip":"3015CE","country":"Netherlands","contacts":[{"name":"A Jager, MD","role":"CONTACT"},{"name":"A Jager, MD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":51.9225,"lon":4.47917}},{"facility":"Franciscus Gasthuis & Vlietland","city":"Rotterdam","country":"Netherlands","geoPoint":{"lat":51.9225,"lon":4.47917}},{"facility":"VieCuri Medisch Centrum voor Noord-Limburg","city":"Venlo","country":"Netherlands","contacts":[{"name":"E Boon, MD","role":"CONTACT"},{"name":"E Boon, MD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":51.37,"lon":6.16806}}]},"ipdSharingStatementModule":{"ipdSharing":"NO","description":"no IPD plan"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-07-01"},"conditionBrowseModule":{"meshes":[{"id":"D000001943","term":"Breast Neoplasms"},{"id":"D000064726","term":"Triple Negative Breast Neoplasms"}],"ancestors":[{"id":"D000009371","term":"Neoplasms by Site"},{"id":"D000009369","term":"Neoplasms"},{"id":"D000001941","term":"Breast Diseases"},{"id":"D000012871","term":"Skin Diseases"}],"browseLeaves":[{"id":"M5220","name":"Breast Neoplasms","asFound":"Breast Cancer","relevance":"HIGH"},{"id":"M30373","name":"Triple Negative Breast Neoplasms","asFound":"Triple Negative Breast Cancer","relevance":"HIGH"},{"id":"M5218","name":"Breast Diseases","relevance":"LOW"},{"id":"M15674","name":"Skin Diseases","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC04","name":"Neoplasms"},{"abbrev":"BC17","name":"Skin and Connective Tissue Diseases"},{"abbrev":"All","name":"All Conditions"}]}},"hasResults":false}